DeepMed Research

TAURX THERAPEUTICS LTD.

🇸🇬Singapore

Country: 🇸🇬Singapore

Ownership: Private

Established: 2002-01-01

Employees: 501

Market Cap: -

Website: http://taurx.com

Clinical Trials

TRx0237 for the Treatment of Early and Mild-Moderate Alzheimer's Disease

Conditions: Alzheimer Disease

First Posted Date: 2018-05-29

Last Posted Date: 2024-09-27

Lead Sponsor: TauRx Therapeutics Ltd

Registration Number: NCT03539380

Safety and Efficacy of TRx0237 in Subjects With Alzheimer's Disease Followed by Open-Label Treatment

Phase 3

Completed

Conditions: Alzheimer Disease

Interventions: Drug: Placebo
Drug: TRx0237 16 mg/day
Drug: TRx0237 8 mg/day

First Posted Date: 2018-02-26

Last Posted Date: 2023-05-24

Lead Sponsor: TauRx Therapeutics Ltd

Target Recruit Count: 598

Registration Number: NCT03446001

Locations: 🇺🇸
Visionary Investigators Network, Miami, Florida, United States
🇺🇸
Finlay Medical Research, Miami, Florida, United States
🇺🇸
Health Care Family Rehab and Research, Miami, Florida, United States

and more 95 locations

Open-Label Study of Leuco-methylthioninium Bis(Hydromethanesulfonate) (LMTM) in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)

Phase 3

Terminated

Conditions: Behavioral Variant Frontotemporal Dementia
Alzheimer's Disease

Interventions: Drug: LMTM

First Posted Date: 2014-09-19

Last Posted Date: 2023-05-24

Lead Sponsor: TauRx Therapeutics Ltd

Target Recruit Count: 913

Registration Number: NCT02245568

Locations: 🇺🇸
Feldman, Robert MD, Laguna Hills, California, United States
🇺🇸
The Shankle Clinic, Newport Beach, California, United States
🇺🇸
Pacific Research Network, San Diego, California, United States

and more 129 locations

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease

Phase 3

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: TRx0237 200 mg/day
Drug: Placebo

First Posted Date: 2012-09-21

Last Posted Date: 2018-03-14

Lead Sponsor: TauRx Therapeutics Ltd

Target Recruit Count: 800

Registration Number: NCT01689233

Locations: 🇦🇺
Discipline of Psychiatry, University of Queensland, Herston, Queensland, Australia
🇺🇸
Brain Matters Research, Delray Beach, Florida, United States
🇺🇸
The Roskamp Institute, Inc., Sarasota, Florida, United States

and more 92 locations

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease

Phase 3

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: TRx0237 250 mg/day
Drug: TRx0237 150 mg/day
Drug: Placebo

First Posted Date: 2012-09-21

Last Posted Date: 2018-03-14

Lead Sponsor: TauRx Therapeutics Ltd

Target Recruit Count: 891

Registration Number: NCT01689246

Locations: 🇺🇸
Brain Matters Research, Delray Beach, Florida, United States
🇵🇱
NZOZ Wielospecjalistyczna Poradnia Lekarska SYNAPSIS, Katowice, Poland
🇵🇱
Gabinet Neurologiczny, Indywidualna Specjalistyczna Praktyka Lekarska, Mosina, Poland

and more 114 locations

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)

Phase 3

Completed

Conditions: Behavioral Variant Frontotemporal Dementia (bvFTD)

Interventions: Drug: TRx0237
Drug: Placebo

First Posted Date: 2012-06-22

Last Posted Date: 2018-03-14

Lead Sponsor: TauRx Therapeutics Ltd

Target Recruit Count: 220

Registration Number: NCT01626378

Locations: 🇺🇸
University Hospitals Case Medical Center, Neurology Clinical Trials Unit, Cleveland, Ohio, United States
🇨🇦
Toronto Memory Program, Toronto, Ontario, Canada
🇺🇸
UNC Department of Neurology, Physicians Office Building, Chapel Hill, North Carolina, United States

and more 64 locations

Safety Study of TRx0237 in Patients Already Taking Medications for Mild and Moderate Alzheimer's Disease

Phase 2

Terminated

Conditions: Alzheimer's Disease

Interventions: Drug: TRx0237
Drug: Placebo

First Posted Date: 2012-06-22

Last Posted Date: 2014-07-11

Lead Sponsor: TauRx Therapeutics Ltd

Target Recruit Count: 9

Registration Number: NCT01626391

Multiple Dose Study of TRx0037

Phase 1

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: TRx0037

First Posted Date: 2010-12-03

Last Posted Date: 2010-12-17

Lead Sponsor: TauRx Therapeutics Ltd

Target Recruit Count: 31

Registration Number: NCT01253499

Comparative Bioavailability in Healthy Elderly Volunteers

Phase 1

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: TRx0037

First Posted Date: 2010-12-03

Last Posted Date: 2010-12-03

Lead Sponsor: TauRx Therapeutics Ltd

Target Recruit Count: 24

Registration Number: NCT01253122

Open Label Study of TRx0014 in Alzheimer's Disease

Phase 2

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: TRx0014

First Posted Date: 2008-05-28

Last Posted Date: 2018-04-27

Lead Sponsor: TauRx Therapeutics Ltd

Target Recruit Count: 111

Registration Number: NCT00684944

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy